1Loa L, Wagstoff J, Autona. Losartan potassium a review of its pharmacology, clinical efficacy and tolerability in management of hypertension. Drugs, 1995;51:820
2Chalmers J, MacMahon Mancis S, et al. 1999 World Health Organization- International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committeee of the World Health Organization. Clin- Exp-Hypertens, 1999;21(5～6): 1009
4Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin Ⅱ receptor antagonists: current status and future issue. J Hypertens 1997; 15(Suppl) :S3
5Goldberg MR, de Mey C, Wroblewski JM, et al. Differential effect of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin Ⅰ and Ⅱ in healthy men. Clin pharmacol Ther, 1996; 59:72
1[1]Chironi G, Gariepy J, Denarie N, et al. Influence of hypertension on early carotid artery remodeling. Arterioscler Thromb Vasc Biol, 2003, 23(8): 1460
2[6]Bataineh A, Raij L. Angiotensin Ⅱ , nitric oxide, and end - organ damage in hypertension. Kidney Int, 1998, 68(Suppl): 14
3[7]Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens, 2001,19(3) :415
